Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: A retrospective study of 47 patients

Yael A. Leshem, Emmilia Hodak, Michael David, Grant James Anhalt, Daniel Mimouni

Research output: Contribution to journalArticle

Abstract

Background: Rituximab is increasingly being appreciated as a remarkably effective treatment for pemphigus, mostly concomitantly with other immunosuppressive medications. The majority of studies have used a single cycle of rituximab with the same dosage as approved for the treatment of lymphomas, ie, 375 mg/m2 weekly × 4 weeks. Rituximab is also approved for the treatment of rheumatoid arthritis, with a different dosing regimen: 1000 mg × 2, days 1 and 15. Objective: We aimed to assess the clinical response of patients with pemphigus to a single cycle of rituximab at the dosage used in rheumatoid arthritis. We also evaluated the response to repeated cycles of rituximab. Methods: A total of 47 patients with pemphigus who were treated with rituximab at a dosage of 1000 mg × 2, days 1 and 15, most with concurrent immunosuppressive medications, were retrospectively studied. Results: Remission rates after the first treatment cycle reached 76%. Repeating the treatment further increased the remission rates to 91%. There was a 22% relapse rate at a median time of 8 months, but 75% of relapsing patients achieved remission again with additional cycles. The side-effect profile was similar to previous reports, except for an immediate postinfusion pemphigus exacerbation in 4 patients. Limitations: This was a retrospective study with a limited follow-up period. Conclusion: The rheumatoid arthritis dosage of rituximab was efficacious and well tolerated in patients with pemphigus. Patients who fail to achieve remission after 1 cycle or patients who relapse seem to benefit from repeated rituximab cycles.

Original languageEnglish (US)
Pages (from-to)404-411
Number of pages8
JournalJournal of the American Academy of Dermatology
Volume68
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Pemphigus
Retrospective Studies
Rheumatoid Arthritis
Therapeutics
Immunosuppressive Agents
Recurrence
Rituximab
Lymphoma

Keywords

  • autoimmune bullous disease
  • pemphigus
  • rheumatoid arthritis
  • rituximab
  • treatment

ASJC Scopus subject areas

  • Dermatology

Cite this

Successful treatment of pemphigus with biweekly 1-g infusions of rituximab : A retrospective study of 47 patients. / Leshem, Yael A.; Hodak, Emmilia; David, Michael; Anhalt, Grant James; Mimouni, Daniel.

In: Journal of the American Academy of Dermatology, Vol. 68, No. 3, 03.2013, p. 404-411.

Research output: Contribution to journalArticle

@article{d8220af8183949beab8ff2c93bcf5870,
title = "Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: A retrospective study of 47 patients",
abstract = "Background: Rituximab is increasingly being appreciated as a remarkably effective treatment for pemphigus, mostly concomitantly with other immunosuppressive medications. The majority of studies have used a single cycle of rituximab with the same dosage as approved for the treatment of lymphomas, ie, 375 mg/m2 weekly × 4 weeks. Rituximab is also approved for the treatment of rheumatoid arthritis, with a different dosing regimen: 1000 mg × 2, days 1 and 15. Objective: We aimed to assess the clinical response of patients with pemphigus to a single cycle of rituximab at the dosage used in rheumatoid arthritis. We also evaluated the response to repeated cycles of rituximab. Methods: A total of 47 patients with pemphigus who were treated with rituximab at a dosage of 1000 mg × 2, days 1 and 15, most with concurrent immunosuppressive medications, were retrospectively studied. Results: Remission rates after the first treatment cycle reached 76{\%}. Repeating the treatment further increased the remission rates to 91{\%}. There was a 22{\%} relapse rate at a median time of 8 months, but 75{\%} of relapsing patients achieved remission again with additional cycles. The side-effect profile was similar to previous reports, except for an immediate postinfusion pemphigus exacerbation in 4 patients. Limitations: This was a retrospective study with a limited follow-up period. Conclusion: The rheumatoid arthritis dosage of rituximab was efficacious and well tolerated in patients with pemphigus. Patients who fail to achieve remission after 1 cycle or patients who relapse seem to benefit from repeated rituximab cycles.",
keywords = "autoimmune bullous disease, pemphigus, rheumatoid arthritis, rituximab, treatment",
author = "Leshem, {Yael A.} and Emmilia Hodak and Michael David and Anhalt, {Grant James} and Daniel Mimouni",
year = "2013",
month = "3",
doi = "10.1016/j.jaad.2012.08.010",
language = "English (US)",
volume = "68",
pages = "404--411",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Successful treatment of pemphigus with biweekly 1-g infusions of rituximab

T2 - A retrospective study of 47 patients

AU - Leshem, Yael A.

AU - Hodak, Emmilia

AU - David, Michael

AU - Anhalt, Grant James

AU - Mimouni, Daniel

PY - 2013/3

Y1 - 2013/3

N2 - Background: Rituximab is increasingly being appreciated as a remarkably effective treatment for pemphigus, mostly concomitantly with other immunosuppressive medications. The majority of studies have used a single cycle of rituximab with the same dosage as approved for the treatment of lymphomas, ie, 375 mg/m2 weekly × 4 weeks. Rituximab is also approved for the treatment of rheumatoid arthritis, with a different dosing regimen: 1000 mg × 2, days 1 and 15. Objective: We aimed to assess the clinical response of patients with pemphigus to a single cycle of rituximab at the dosage used in rheumatoid arthritis. We also evaluated the response to repeated cycles of rituximab. Methods: A total of 47 patients with pemphigus who were treated with rituximab at a dosage of 1000 mg × 2, days 1 and 15, most with concurrent immunosuppressive medications, were retrospectively studied. Results: Remission rates after the first treatment cycle reached 76%. Repeating the treatment further increased the remission rates to 91%. There was a 22% relapse rate at a median time of 8 months, but 75% of relapsing patients achieved remission again with additional cycles. The side-effect profile was similar to previous reports, except for an immediate postinfusion pemphigus exacerbation in 4 patients. Limitations: This was a retrospective study with a limited follow-up period. Conclusion: The rheumatoid arthritis dosage of rituximab was efficacious and well tolerated in patients with pemphigus. Patients who fail to achieve remission after 1 cycle or patients who relapse seem to benefit from repeated rituximab cycles.

AB - Background: Rituximab is increasingly being appreciated as a remarkably effective treatment for pemphigus, mostly concomitantly with other immunosuppressive medications. The majority of studies have used a single cycle of rituximab with the same dosage as approved for the treatment of lymphomas, ie, 375 mg/m2 weekly × 4 weeks. Rituximab is also approved for the treatment of rheumatoid arthritis, with a different dosing regimen: 1000 mg × 2, days 1 and 15. Objective: We aimed to assess the clinical response of patients with pemphigus to a single cycle of rituximab at the dosage used in rheumatoid arthritis. We also evaluated the response to repeated cycles of rituximab. Methods: A total of 47 patients with pemphigus who were treated with rituximab at a dosage of 1000 mg × 2, days 1 and 15, most with concurrent immunosuppressive medications, were retrospectively studied. Results: Remission rates after the first treatment cycle reached 76%. Repeating the treatment further increased the remission rates to 91%. There was a 22% relapse rate at a median time of 8 months, but 75% of relapsing patients achieved remission again with additional cycles. The side-effect profile was similar to previous reports, except for an immediate postinfusion pemphigus exacerbation in 4 patients. Limitations: This was a retrospective study with a limited follow-up period. Conclusion: The rheumatoid arthritis dosage of rituximab was efficacious and well tolerated in patients with pemphigus. Patients who fail to achieve remission after 1 cycle or patients who relapse seem to benefit from repeated rituximab cycles.

KW - autoimmune bullous disease

KW - pemphigus

KW - rheumatoid arthritis

KW - rituximab

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=84873712428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873712428&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2012.08.010

DO - 10.1016/j.jaad.2012.08.010

M3 - Article

C2 - 23044076

AN - SCOPUS:84873712428

VL - 68

SP - 404

EP - 411

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 3

ER -